Union Investment selects Premialab
0
This collaboration reflects Union Investment's ongoing focus on innovation and evidence-based decision-making in a constantly evolving investment environment.
"We chose to work with Premialab because of the depth and quality of their QIS data," said Sebastian Rohm, Head of Alternative Risk Premia at Union Investment. "Premialab's tools - particularly for portfolio construction, market analysis, and stress testing - play a key role in supporting our investment framework. The platform also helps us improve operational processes by simplifying data handling and reporting, which ultimately allows us to use our resources more efficiently."
Premialab's platform is powered by a unique dataset collected directly from 18 major global investment banks. It supports institutional investors - including asset managers, wealth managers, pension plans, and sovereign wealth funds - in refining asset allocation, selecting top-performing strategies, and maintaining effective risk control.
"Partnering with Union Investment is an exciting step forward for us as we continue to grow our presence in Germany and across Europe," said Neil Richards, Head of EMEA Business Development at Premialab.
Adrien Géliot, CEO of Premialab, commented: "We're seeing a sharp rise in the adoption of QIS, as institutional investors increasingly turn to these strategies as liquid, transparent, and cost-efficient performance engines. Premialab sits at the heart of this transformation, uniquely positioned to deliver clarity and insight across a rapidly growing universe of systematic strategies. We are delighted to partner with Union Investment and bring our data and risk monitoring capabilities to one of the world's leading investment firms."
Premialab's multi-asset, multi-region platform handles more than 10 million data points every day and analyzes over 6,000 investable systematic strategies. Serving clients with total AUM of around $20 trillion, the platform - along with Premialab Pure Factors® - enables comprehensive quantitative strategy selection, in-depth due diligence, advanced risk assessment, and enhanced regulatory reporting.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
SoftBank shares surge to record after optimism for AI prospects boosted Q1 earnings
TOKYO, Aug 8 (Reuters) - Shares in SoftBank Group (9984.T), opens new tab jumped more than 13% to a record high on Friday morning in a show of investor support for the Japanese technology investor's AI push after first quarter profit beat expectations. SoftBank's share price hit 14,205 yen at the close of morning trading. SoftBank has announced a series of mammoth investments this year, including committing $30 billion to ChatGPT maker OpenAI, as well as leading the financing for Stargate - a $500 billion data centre project in the United States. The firm beat analysts' expectations to report a net profit of 421.8 billion yen ($2.87 billion) for the April-June quarter, compared to a loss in the same period a year ago. Market enthusiasm for AI-related companies also pushed up valuations for its portfolio of listed and unlisted technology companies such that SoftBank's loan to value ratio improved to 17% at the end of June compared to 18% at the end of March. The results were "evidence of SoftBank's quality diversified portfolio, strong underlying fundamentals, thematic/secular tailwinds for its equity holdings, and the resilience of its balance sheet," Macquarie analyst Paul Golding wrote in a note. SoftBank was the biggest contributor to gains for Japan's Topix index (.TOPX), opens new tab, which rose some 1.5% to trade above the 3,000 point mark for the first time in its history. The jump will provide some relief to SoftBank investors as its shares have traded at a more than 50% discount to the value of its assets over the past five quarters. "Active investors scooped up SoftBank Group shares to beat the Topix's gain," said Seiichi Suzuki, chief equity market analyst at Tokai Tokyo Research Institute. "When the main indexes rise, they need to buy heavyweights that are rising. SoftBank's strong earnings and the Topix's gains came at the same time."
Reuters
2 hours ago
- Reuters
CureVac settles mRNA patent dispute litigation with Pfizer and BioNTech
Aug 7 (Reuters) - German drugmaker CureVac ( opens new tab and GSK (GSK.L), opens new tab reached an agreement with BioNTech ( opens new tab and Pfizer (PFE.N), opens new tab on Thursday to resolve a years-long patent dispute related to mRNA-based COVID-19 vaccines, CureVac said. As part of the settlement, CureVac and GSK will receive a combined payment of $740 million and single-digit royalties on sales of COVID-19 vaccines in the U.S. going forward. CureVac will also grant BioNTech and Pfizer a non-exclusive license to manufacture, use, import and sell mRNA-based COVID-19 and influenza products in the U.S. The settlement comes after BioNTech agreed to acquire its domestic peer CureVac in a $1.25 billion all-stock deal in June. Three years ago, CureVac had filed a patent lawsuit against BioNTech over its use of mRNA technology, seeking fair compensation from the company and two of its subsidiaries for infringement of its intellectual property rights. CureVac had said that its claim to intellectual property rights was based on more than two decades of work on mRNA technology, some of which was used by BioNTech and Pfizer for the development and sale of their Comirnaty coronavirus vaccine. CureVac's efforts to develop an mRNA-based COVID-19 vaccine did not come to fruition during the pandemic, whereas BioNTech and its partner Pfizer chalked up more than $40 billion in combined vaccine sales in 2021 and 2022.
Reuters
2 hours ago
- Reuters
Meta selects PIMCO, Blue Owl for $29 billion data center financing, Bloomberg News reports
Aug 7 (Reuters) - Meta (META.O), opens new tab has selected investment management firm PIMCO and alternative asset manager Blue Owl Capital (OWL.N), opens new tab for a $29 billion financing deal related to its data center projects in rural Louisiana, Bloomberg News reported on Thursday. Reuters could not immediately verify the report.
